Key facts
- Delphinus Medical Technologies’s last known valuation is $210.0M (Aug 2023).
- It has raised $161.4M across 5 recorded rounds; the latest was Early Stage VC ($5.0M) in Jun 2023.
- Notable investors include Invest Detroit Ventures, Arboretum Ventures, Beringea, University of Michigan Endowment, InvestMichigan! Program — 14 tracked in total.
- Delphinus Medical Technologies has filed 9 Form Ds with the SEC since 2010, most recently Apr 2025 ($27.6M sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Delphinus Medical Technologies
Funding rounds
5 roundsAbout Delphinus Medical Technologies
Developer of an ultrasound system designed to transform the early detection of breast cancer. The company's system differentiates benign from malignant masses in breast cancer cases with the use of sound and water and utilizes a ring transducer to transmit and receive ultrasound signals, enabling medical professionals to better define and diagnose breast cancers and provide a better patient experience for women regardless of age, without concern of radiation or discomfort.
- Sector
- Healthcare
- HQ
- Novi, MI, United States
- Founded
- 2010
- Employees
- 51
- Website
- delphinusmt.com/
- Ownership
- Privately Held (backing)
Delphinus Medical Technologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Delphinus Medical Technologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Delphinus Medical Technologies in its N-PORT filings yet. We sweep new filings monthly.